Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 201–300 of 1,017
Imaging and Nanomedicine in Inflammatory Atherosclerosis
Mulder, W. J. M., Jaffer, F. A., Fayad, Z. A., & Nahrendorf, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005101 · Cited by 192
A Mendelian randomization study of the effects of blood lipids on breast cancer risk
Nowak, C., & Ärnlöv, J. (2018) · Nature Communications · doi:10.1038/s41467-018-06467-9 · Cited by 190
Jones, M. L., Tomaro-Duchesneau, C., Martoni, C. J., & Prakash, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.758706 · Cited by 190
“However, reports have indicated that new drugs such as ezetimibe and torcetrapib, either have not shown an incremental reduction of secondary endpoints in atherosclerotic disease, such as carotid intimamedia thickness [27,28], or have had unanticipated adverse effects [29].”
BackgroundABC transporters, atherosclerosis and inflammation
Fitzgerald, M. L., Mujawar, Z., & Tamehiro, N. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.01.011 · Cited by 190
“[150] Barter PJ, Caulfield M, Eriksson M, et al.”
BackgroundMichael Gibson, C., Korjian, S., Tricoci, P., Daaboul, Y., Yee, M., Jain, P., Alexander, J. H., Steg, P. G., Lincoff, A. M., Kastelein, J. J. P., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.025687 · Cited by 191
Self-citationRapid regression of atherosclerosis: insights from the clinical and experimental literature
Williams, K. J., Feig, J. E., & Fisher, E. A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1086 · Cited by 189
“The Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) study”
MethodZhao, Q., Chen, Y., Wang, J., & Small, D. S. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz142 · Cited by 188
Laboratory Assessment of HDL Heterogeneity and Function
Movva, R., & Rader, D. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101923 · Cited by 188
Yudkin, J. S., Lipska, K. J., & Montori, V. M. (2011) · BMJ · doi:10.1136/bmj.d7995 · Cited by 185
Effects of curcumin on HDL functionality
Ganjali, S., Blesso, C. N., Banach, M., Pirro, M., Majeed, M., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.008 · Cited by 186
Badimon, L., & Vilahur, G. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06480.x · Cited by 186
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-2085133501150912 · Cited by 186
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease
Budoff, M. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.004 · Cited by 184
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
Tardif, J.-C., Rhéaume, E., Lemieux Perreault, L.-P., Grégoire, J. C., Feroz Zada, Y., Asselin, G., Provost, S., Barhdadi, A., Rhainds, D., L’Allier, P. L., et al. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000663 · Cited by 185
“ing HDL-cholesterol levels by ≈70% although elevations of aldosterone levels and blood pressure observed in some patients may have contributed to the negative findings.(3) Dalcetrapib is another cholesteryl ester transfer protein inhibitor that raises HDL-cholesterol levels by ≈30%, without effects on circulating neur…”
BackgroundSelf-citationHDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 182
Schwartz, G. G., Olsson, A. G., Ballantyne, C. M., Barter, P. J., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Shah, P. K., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.09.017 · Cited by 183
Self-citationHigh-Density Lipoproteins: – Multifunctional but Vulnerable Protections from Atherosclerosis –
Annema, W., & von Eckardstein, A. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-1025 · Cited by 183
APOA1: a Protein with Multiple Therapeutic Functions
Cochran, B. J., Ong, K.-L., Manandhar, B., & Rye, K.-A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00906-7 · Cited by 179
Mineralocorticoid receptors in vascular function and disease
McCurley, A., & Jaffe, I. Z. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.014 · Cited by 178
“…in vascular function lending support for a role for Aldo in directly regulating vascular function in vivo in humans(Farquharson and Struthers, 2000; Gonzaga and Calhoun, 2008; Nissen et al., 2007; Bots et al., 2007; Barter et al., 2007; Nicholls et al., 2008; Vergeer et al., 2008; Duriez, 2007).”
BackgroundEffects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
McTaggart, F., & Jones, P. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6113-z · Cited by 177
Nicholls, S. J., Ditmarsch, M., Kastelein, J. J., Rigby, S. P., Kling, D., Curcio, D. L., Alp, N. J., & Davidson, M. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01936-7 · Cited by 174
Self-citationHDL dysfunction in diabetes: causes and possible treatments
Farbstein, D., & Levy, A. P. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.182 · Cited by 174
(2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.007 · Cited by 174
High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events
Jia, C., Anderson, J. L. C., Gruppen, E. G., Lei, Y., Bakker, S. J. L., Dullaart, R. P. F., & Tietge, U. J. F. (2021) · Circulation · doi:10.1161/circulationaha.120.050808 · Cited by 170
Nicholls, S. J., Gordon, A., Johansson, J., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Taylor, A., Borgman, M., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.015 · Cited by 174
Self-citationResidual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 172
Self-citationThe dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
High-Density Lipoprotein Cholesterol and Mortality: Too Much of a Good Thing?
Hamer, M., O’Donovan, G., & Stamatakis, E. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310587 · Cited by 171
HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis
Tsompanidi, E. M., Brinkmeier, M. S., Fotiadou, E. H., Giakoumi, S. M., & Kypreos, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.034 · Cited by 170
“While reviewing the literature, it also becomes clear that despite he vast amount of existing knowledge on HDL, more studies re needed to determine the interrelation of the atheroprotective roperties of HDL to each other, as well as their individual signifcance and contribution towards the prevention of atherosclerosi…”
InfluentialInflammation modulates human HDL composition and function in vivo
de la Llera Moya, M., McGillicuddy, F. C., Hinkle, C. C., Byrne, M., Joshi, M. R., Nguyen, V., Tabita-Martinez, J., Wolfe, M. L., Badellino, K., Pruscino, L., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.032 · Cited by 168
Update on strategies to increase HDL quantity and function
Duffy, D., & Rader, D. J. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.94 · Cited by 169
“Finally, as will be discussed in greater detail below, treatment with torceptrapib, an inhibitor of cholesteryl ester transfer protein (CETP), was associated with adverse cardiovascular outcomes despite robust raising of HDL-cholesterol levels”
MethodWhere are we with probucol: A new life for an old drug?
Yamashita, S., & Matsuzawa, Y. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.04.002 · Cited by 167
Riwanto, M., & Landmesser, U. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r037762 · Cited by 167
Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists
Fitridge, R., & Thompson, M. M. (2011) · Cited by 183
Feig, J. E., Hewing, B., Smith, J. D., Hazen, S. L., & Fisher, E. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.300760 · Cited by 169
“Another CETP inhibitor, torcetrapib, which potently increases plasma levels of HDL-C and apoAI and significantly lowers that of LDL-C, was also judged a failure in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) trial.(70) It has been presumed that this invol…”
BackgroundCiani, O., Buyse, M., Garside, R., Pavey, T., Stein, K., Sterne, J. A. C., & Taylor, R. S. (2013) · BMJ · doi:10.1136/bmj.f457 · Cited by 165
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 164
Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis
Mehta, N. N., Li, R., Krishnamoorthy, P., Yu, Y., Farver, W., Rodrigues, A., Raper, A., Wilcox, M., Baer, A., DerOhannesian, S., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.06.068 · Cited by 162
“Indeed HDL composition and function have been of specific interest in face of recent failure the cholesterol ester transfer protein (CETP) inhibitor torcetrapib and more recently niacin to reduce CVD despite their HDL-C raising effects [17].”
BackgroundHDL metabolism and activity in chronic kidney disease
Vaziri, N. D., Navab, M., & Fogelman, A. M. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.36 · Cited by 163
“However, a clinical trial of torcetrapib, a promising CETP inhibitor, in patients at high risk of coronary events was prematurely halted because of an unexpected increase in adverse cardiovascular outcomes associated with its administration compared with placebo despite a marked increase in plasma HDL level”
BackgroundLu, H., & Daugherty, A. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305380 · Cited by 160
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
New insight into dyslipidemia‐induced cellular senescence in atherosclerosis
Xiang, Q., Tian, F., Xu, J. R., Du, X., Zhang, S., & Liu, L. (2022) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12866 · Cited by 180
“Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society. of cardiovascular events (Barter et al., 2007; Lincoff et al., 2017).”
BackgroundDysfunctional HDL as a Diagnostic and Therapeutic Target
Smith, J. D. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179226 · Cited by 170
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156
“Recently, however, despite a 72% increase in HDL cholesterol, patients treated with the CETP-inhibitor torcetrapib in the ILLUMINATE (Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events) trial had a paradoxical increase in mortality and an increase in major cardiovascular events…”
BackgroundInfluentialLipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease
Vaziri, N. D., & Norris, K. (2011) · Blood Purification · doi:10.1159/000321845 · Cited by 155
“and (g) contribution to cholesterol enrichment and triglyceride depletion of IDL and its maturation to LDL via cholesteryl ester transfer protein (CETP)-mediated exchange of cholesterol ester for triglycerides. This process is referred to as indirect RCT as it employs LDL to dispose a portion of HDL’s cholesterol carg…”
BackgroundRay, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P., & Kastelein, J. J. P. (2018) · Circulation · doi:10.1161/circulationaha.118.034710 · Cited by 154
Self-citationAdvances in our understanding of the structure and functionality of edible fats and fat mimetics
Marangoni, A. G., van Duynhoven, J., Acevedo, N. C., Nicholson, R. A., & Patel, A. R. (2019) · Soft Matter · doi:10.1039/c9sm01704f · Cited by 171
Niesor, E. J., Magg, C., Ogawa, N., Okamoto, H., von der Mark, E., Matile, H., Schmid, G., Clerc, R. G., Chaput, E., Blum-Kaelin, D., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m008706 · Cited by 152
Feig, J. E., Shang, Y., Rotllan, N., Vengrenyuk, Y., Wu, C., Shamir, R., Torra, I. P., Fernandez-Hernando, C., Fisher, E. A., & Garabedian, M. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028534 · Cited by 150
“Taken together, our findings indicate that statins, in addition to their traditionally considered effects on atherosclerosis by retarding plaque progression through lowering LDL-C, may also have additional clinical benefits by accelerating plaque regression through enhancing CCR7 expression and emigration of CD68+ mac…”
Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk
Zewinger, S., Drechsler, C., Kleber, M. E., Dressel, A., Riffel, J., Triem, S., Lehmann, M., Kopecky, C., Säemann, M. D., Lepper, P. M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv352 · Cited by 150
“Large trials using the CETP inhibitors torcetrapib and dalcetrapib did not show a reduction of cardiovascular outcomes.(31,32) In these study programmes, a substantial proportion of Figure 3 HRs of tertiles of measured and calculated biologically effective HDL-C for the primary composite endpoint as well as all-cause…”
MethodHigh-Density Lipoprotein Function and Dysfunction in Health and Disease
Chiesa, S. T., & Charakida, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-06846-w · Cited by 165
Novel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
“In the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE)”
BackgroundHu, X., Dietz, J. D., Xia, C., Knight, D. R., Loging, W. T., Smith, A. H., Yuan, H., Perry, D. A., & Keiser, J. (2009) · Endocrinology · doi:10.1210/en.2008-1512 · Cited by 150
“These results were not anticipated because numerous preclinical and epidemiological studies suggest a beneficial antiatherosclerotic effect of CETP inhibition and HDL-C elevation (1, 2, 6).”
BackgroundInfluentialTargeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy, D. J., & Yellon, D. M. (2008) · Heart · doi:10.1136/hrt.2007.125401 · Cited by 149
Hirata, A., Sugiyama, D., Watanabe, M., Tamakoshi, A., Iso, H., Kotani, K., Kiyama, M., Yamada, M., Ishikawa, S., Murakami, Y., et al. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.01.014 · Cited by 148
HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy
Linton, M. F., Yancey, P. G., Tao, H., & Davies, S. S. (2023) · Circulation Research · doi:10.1161/circresaha.123.321563 · Cited by 175
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60312-2 · Cited by 148
Reiner, Ž. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.002 · Cited by 147
Meuwese, M. C., de Groot, E., Duivenvoorden, R., Trip, M. D., Ose, L., Maritz, F. J., Basart, D. C. G., Kastelein, J. J. P., Habib, R., Davidson, M. H., et al. (2009) · JAMA · doi:10.1001/jama.301.11.1131 · Cited by 146
Self-citationHDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 160
Self-citationCholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Barter, P. J., & Rye, K.-A. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024075 · Cited by 146
“cholesterol in the group receiving torcetrapib, the trial was terminated early because of a statistically significant excess of deaths associated with treatment with torcetrapib (30).”
InfluentialSelf-citationSystemic and renal lipids in kidney disease development and progression
WAHL, P. W., Ducasa, G. M., & Fornoni, A. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00375.2015 · Cited by 152
Mechanisms and Treatment of Dyslipidemia in Diabetes
Bahiru, E. M., Hsiao, R., Philipson, D. J., & Watson, K. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01455-w · Cited by 183
Hewing, B., Parathath, S., Barrett, T., Chung, W. K. K., Astudillo, Y. M., Hamada, T., Ramkhelawon, B., Tallant, T. C., Yusufishaq, M. S. S., DiDonato, J. A., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.303044 · Cited by 145
“However, recent reports from the large clinical outcome studies aimed at raising HDL-C levels with either cholesteryl ester transfer protein inhibitors or niacin (as add-on therapy to statins) have thus far failed to demonstrate clinical benefit.(17,18,27) Similarly, results from a recent Mendelian randomization study…”
ResultThe impact of aerobic exercise on HDL quantity and quality: a narrative review
Franczyk, B., Gluba-Brzózka, A., Ciałkowska-Rysz, A., Ławiński, J., & Rysz, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054653 · Cited by 142
Jensen, M. K., Rimm, E. B., Furtado, J. D., & Sacks, F. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.111.000232 · Cited by 142
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Self-citationCholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
“Post hoc analyses attribute the increase in BP to off-target effects of increased aldosterone leading to electrolyte changes and related metabolic effects (20).”
BackgroundMethodInfluentialHigh-density lipoprotein subclasses and their relationship to cardiovascular disease
Superko, H. R., PENDYALA, L. K., Williams, P. T., Momary, K. M., King, S. B., & Garrett, B. C. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.03.001 · Cited by 152
Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 137
Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs
Everett, B. M., Smith, R. J., & Hiatt, W. R. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1508120 · Cited by 112
Zhong, G.-C., Huang, S.-Q., Peng, Y., Wan, L., Wu, Y.-Q.-L., Hu, T.-Y., Hu, J.-J., & Hao, F.-B. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320914756 · Cited by 136
Emerging roles for cholesterol and lipoproteins in lung disease
Gowdy, K. M., & Fessler, M. B. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.06.002 · Cited by 138
Stein, E. A., Stroes, E. S. G., Steiner, G. A., Buckley, B. M., Capponi, A. M., Burgess, T., Niesor, E. J., Kallend, D. G., & Kastelein, J. J. P. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.061 · Cited by 136
Self-citationWilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Circulation · doi:10.1161/cir.0000000000000626 · Cited by 135
Is raising HDL a futile strategy for atheroprotection?
JOY, T. R., & Hegele, R. A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2489 · Cited by 155
“However, the recent unexpected association of torcetrapib — an agent that increases plasma HDL-C — with increased cardiovascular mortality has led to the discontinuation of further trials involving this dru”
BackgroundVegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials
Koch, C. A., Kjeldsen, E. W., & Frikke-Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad211 · Cited by 134
Foundations of Lifestyle Medicine and its Evolution
Lippman, D., Stump, M., Veazey, E., Guimarães, S. T., Rosenfeld, R. M., Kelly, J. H., Ornish, D. M., & Katz, D. L. (2024) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2023.11.004 · Cited by 188
Adipocyte Modulation of High-Density Lipoprotein Cholesterol
Zhang, Y., McGillicuddy, F. C., Hinkle, C. C., O'Neill, S., Glick, J. M., Rothblat, G. H., & Reilly, M. P. (2010) · Circulation · doi:10.1161/circulationaha.109.897330 · Cited by 135
Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134
“HDL elevators, Torcetrapib and Dalcetrapib, in phase 3 clinical studies, have shown disappointing results despite substantial increases in HDL-C [56,57].”
BackgroundThe role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis
Masson, D., Jiang, X.-C., Lagrost, L., & Tall, A. R. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800061-jlr200 · Cited by 131
“Unfortunately, a large phase III clinical trial called ILLUMINATE involving torcetrapib, was stopped prematurely as a result of an excess of deaths and cardiovascular disease in the group receiving torcetrapib and atorvastatin compared to atorvastatin alone (26).”
BackgroundSelf-citationVergeer, M., Bots, M. L., van Leuven, S. I., Basart, D. C., Sijbrands, E. J., Evans, G. W., Grobbee, D. E., Visseren, F. L., Stalenhoef, A. F., Stroes, E. S., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.772665 · Cited by 134
Self-citationHDL in Atherosclerotic Cardiovascular Disease: In Search of a Role
Casula, M., Colpani, O., Xie, S., Catapano, A. L., & Baragetti, A. (2021) · Cells · doi:10.3390/cells10081869 · Cited by 162
“2007 [66] Torcetrapib ILLUMINATE 15,067 patients at high cardiovascular risk 1–2 years HDL-C: +72% LDL-C: −25% Increased risk of cardiovascular events (HR 1.”
BackgroundTrinder, M., Walley, K. R., Boyd, J. H., & Brunham, L. R. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313381 · Cited by 133
Triglycerides and HDL Cholesterol
Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., & Harats, D. (2009) · Diabetes Care · doi:10.2337/dc09-s343 · Cited by 132
“FUTURE PROSPECTS — The concept of cholesterol ester transfer protein (CETP) inhibition suffered a serious blow when the results of the ILLUMINATE trial demonstrated an increase in adverse events in patients treated with torcetrapib (42).”
Backgroundvan der Made, S. M., Plat, J., & Mensink, R. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118393 · Cited by 131
Otis, J. P., Zeituni, E. M., Thierer, J. H., Anderson, J. L., Brown, A., Boehm, E. D., Cerchione, D. M., Ceasrine, A. M., Avraham‐Davidi, I., Tempelhof, H., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018754 · Cited by 152
“…cholesterol to the liver; however, mice lacking APOA-I have normal biliary cholesterol secretion (Amigo et al., 2011) and some pharmaceutical agents that raise HDL-C fail to provide the protection observed with naturally high HDL cholesterol levels (Barter et al., 2007; Boden et al., 2011).”
BackgroundGenetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis
Harrison, S. C., Holmes, M. V., Burgess, S., Asselbergs, F. W., Jones, G. T., Baas, A. F., van ’t Hof, F. N., de Bakker, P. I. W., Blankensteijn, J. D., Powell, J. T., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4293 · Cited by 131
Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting
Cziraky, M. J., Watson, K. E., & Talbert, R. L. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s8-a.1 · Cited by 131
de Lorgeril, M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.184 · Cited by 130
Vasan, R. S., Pencina, M. J., Robins, S. J., Zachariah, J. P., Kaur, G., D'Agostino, R. B., & Ordovas, J. M. (2009) · Circulation · doi:10.1161/circulationaha.109.872705 · Cited by 131
The Harbin Consensus Conference Workshop Group, Chairs:, C., Legro, R. S., Wu, X., Scientific Committee:, Barnhart, K. T., Farquhar, C., Fauser, B. C. J. M., Mol, B., Legro, R. S., et al. (2014) · Human Reproduction · doi:10.1093/humrep/deu218 · Cited by 129
Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome
Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J., Moore, A. B., Marcovina, S., Brunzell, J., Knopp, R. H., Zhao, X.-Q., & Heinecke, J. W. (2008) · Circulation · doi:10.1161/circulationaha.108.770669 · Cited by 130
Novel anti-inflammatory therapies for the treatment of atherosclerosis
Khan, R., Spagnoli, V., Tardif, J., & L’Allier, P. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.783 · Cited by 139
Self-citationDavidson, M., Meyer, P. M., Haffner, S., Feinstein, S., D’Agostino, R., Kondos, G. T., Perez, A., Chen, Z., & Mazzone, T. (2008) · Circulation · doi:10.1161/circulationaha.107.746610 · Cited by 128
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.